Vitamin D Analogs as Anti-Carcinogenic Agents

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 16, 12 Issues, 2016

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Vitamin D Analogs as Anti-Carcinogenic Agents

Anti-Cancer Agents in Medicinal Chemistry, 6(1): 53-71.

Author(s): E. S. Agoston, M. A. Hatcher, T. W. Kensler and G H Posner.

Affiliation: Department of Chemistry, Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218-2685, USA;


Deltanoids are the class of compounds comprising all natural and synthetic vitamin D molecules. The anti-proliferative, pro-differentiation, and pro-apoptotic properties of deltanoids have garnered interest in the fields of cancer chemoprevention and chemotherapy. The naturally occurring, biologically active form of vitamin D, 1,25(OH)2D3, causes hypercalcemia at pharmacologically relevant doses which forms a major obstacle in the clinical development of this compound. Design of new deltanoids has shown promise in separating the beneficial effects from the toxic effects. The Vitamin D receptor (VDR) is a major target for deltanoid design, and the structural features of deltanoid binding have been described. Effective compounds must also exhibit beneficial pharmacokinetic properties in vivo, and the plasma vitamin D binding protein (DBP) is likely to play an important role in the success of deltanoids in the clinic. Further, dual strategies of avoiding vitamin D toxicity through altering the dosing sc hedule and using less toxic deltanoids are in development. The three main categories of structural modification to the vitamin D backbone include the C,D-ring, the A-ring, and the C,D-ring side chain, and the ways each area has impacted efficacy and toxicity have been described through structure-activity relationships (SARs). Lastly, there is evidence that deltanoids can enhance the activity of other chemopreventive agents. The use of a cocktail approach will be discussed as a potential avenue for deltanoids in chemoprevention and chemotherapy.


Structure-activity relationships, combination chemoprevention, pharmacokinetics, vitamin D receptor, vitamin D binding protein, CYP24 inhibition, deltanoids, cancer chemotherapy.

Download Free Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 6
Issue Number: 1
First Page: 53
Last Page: 71
Page Count: 19
DOI: 10.2174/187152006784111369

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science